Sign In
Buy GLMD
$0.680
-0.0111 (-1.61%)
At Close: Jun 03, 2026
Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6
12:30pm, Wednesday, 30'th Oct 2019
TEL AVIV, Israel , Oct. 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
12:14pm, Friday, 11'th Oct 2019
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra
The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
11:31am, Thursday, 10'th Oct 2019
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct.
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
12:00am, Thursday, 03'rd Oct 2019Galmed Pharmaceuticals Initiated ARMOR, a Phase 3/4 Registrational Study of Aramchol in Subjects With NASH and Fibrosis
12:00pm, Thursday, 26'th Sep 2019
TEL AVIV, Israel, Sept. 26, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targ
Should You Buy Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) For This Reason?
05:05pm, Thursday, 19'th Sep 2019
Trailing twelve-month data shows us that Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) earnings loss has accumulated to...
